These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 11151749)
41. The relationship between plasma levels of clozapine and N-desmethyclozapine as well as M1 receptor polymorphism with cognitive functioning and associated cortical activity in schizophrenia. Kır Y; Baskak B; Kuşman A; Sayar-Akaslan D; Özdemir F; Sedes-Baskak N; Süzen HS; Baran Z Psychiatry Res Neuroimaging; 2020 Sep; 303():111128. PubMed ID: 32593951 [TBL] [Abstract][Full Text] [Related]
43. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. Melkersson KI; Scordo MG; Gunes A; Dahl ML J Clin Psychiatry; 2007 May; 68(5):697-704. PubMed ID: 17503978 [TBL] [Abstract][Full Text] [Related]
44. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Seppälä NH; Leinonen EV; Lehtonen ML; Kivistö KT Pharmacol Toxicol; 1999 Nov; 85(5):244-6. PubMed ID: 10608488 [TBL] [Abstract][Full Text] [Related]
45. Automated determination of clozapine and major metabolites in serum and urine. Weigmann H; Bierbrauer J; Härtter S; Hiemke C Ther Drug Monit; 1997 Aug; 19(4):480-8. PubMed ID: 9263393 [TBL] [Abstract][Full Text] [Related]
46. Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels. Wehring HJ; Elsobky T; McEvoy JP; Vyas G; Richardson CM; McMahon RP; DiPaula BA; Liu F; Sullivan K; Buchanan RW; Feldman S; McMahon EM; Kelly DL Psychiatr Q; 2018 Mar; 89(1):73-80. PubMed ID: 28466366 [TBL] [Abstract][Full Text] [Related]
47. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions. Tan MSA; Honarparvar F; Falconer JR; Parekh HS; Pandey P; Siskind DJ Psychopharmacology (Berl); 2021 Mar; 238(3):615-637. PubMed ID: 33410989 [TBL] [Abstract][Full Text] [Related]
48. Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Chang WH; Lin SK; Lane HY; Wei FC; Hu WH; Lam YW; Jann MW Prog Neuropsychopharmacol Biol Psychiatry; 1998 Jul; 22(5):723-39. PubMed ID: 9723115 [TBL] [Abstract][Full Text] [Related]
49. The usefulness of monitored therapy using Clozapine concentration in the blood serum for determining drug dose in Polish schizophrenic patients. Piwowarska J; Radziwoń-Zaleska M; Dmochowska M; Szepietowska E; Matsumoto H; Sygitowicz G; Pilc A; Łukaszkiewicz J Pharmacol Rep; 2016 Dec; 68(6):1120-1125. PubMed ID: 27588387 [TBL] [Abstract][Full Text] [Related]
50. Assay for quantitation of clozapine and its metabolite N-desmethylclozapine in human plasma by high-performance liquid chromatography with ultraviolet detection. Edno L; Combourieu I; Cazenave M; Tignol J J Pharm Biomed Anal; 1997 Oct; 16(2):311-8. PubMed ID: 9408849 [TBL] [Abstract][Full Text] [Related]
51. Variability of the in vivo metabolism of clozapine. Raedler TJ; Hinkelmann K; Wiedemann K Clin Neuropharmacol; 2008; 31(6):347-52. PubMed ID: 19050412 [TBL] [Abstract][Full Text] [Related]
52. Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia. Costa-Dookhan KA; Rajji TK; Tran VN; Bowden S; Mueller DJ; Remington GJ; Agarwal SM; Hahn MK Sci Rep; 2021 Jan; 11(1):2004. PubMed ID: 33479273 [TBL] [Abstract][Full Text] [Related]
53. Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients. Lee ST; Ryu S; Nam HJ; Lee SY; Hong KS Int Clin Psychopharmacol; 2009 May; 24(3):139-44. PubMed ID: 19194306 [TBL] [Abstract][Full Text] [Related]
54. Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics. Tóth K; Csukly G; Sirok D; Belic A; Kiss Á; Háfra E; Déri M; Menus Á; Bitter I; Monostory K Int J Neuropsychopharmacol; 2017 Jul; 20(7):529-537. PubMed ID: 28340122 [TBL] [Abstract][Full Text] [Related]
55. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241 [TBL] [Abstract][Full Text] [Related]
56. Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Olesen OV; Thomsen K; Jensen PN; Wulff CH; Rasmussen NA; Refshammer C; Sørensen J; Bysted M; Christensen J; Rosenberg R Psychopharmacology (Berl); 1995 Feb; 117(3):371-8. PubMed ID: 7770613 [TBL] [Abstract][Full Text] [Related]
57. Determination of clozapine and its metabolite, N-desmethylclozapine, in serum microsamples by high-performance liquid chromatography and its application to pharmacokinetics in rats. Ma F; Lau CE J Chromatogr B Biomed Sci Appl; 1998 Aug; 712(1-2):193-8. PubMed ID: 9698242 [TBL] [Abstract][Full Text] [Related]